INTRODUCTION {#sec1-1}
============

Myelomeningocele in children have a negative impact on both lower urinary tract and bowel functioning; causing upper urinary tract dilatation, vesicoureteric reflux, recurrent UTIs, as well as urinary and stool incontinence (SI).\[[@ref1][@ref2]\]

The majority of patients improve with conservative management of anticholinergics medications, antibiotic prophylaxis, and clean intermittent catheterization (CIC).\[[@ref3]\] For patients who fail to respond to such management, major reconstruction surgery seems to be unavoidable.\[[@ref4]\]

At the same time, SI unfortunately more difficult to manage conservatively using diet modification and bulking agents; a significant percentage of patients will end up requiring diapers, despite urinary continence.\[[@ref5]\]

Late in 20^th^ century, major reconstructive surgery-bladder enterocystoplasties and Malone Antegrade Continence Enema (MACE)-have been widely used and accepted as a gold-standard management of noncompliant neuropathic bladder and bowel.

Over the following years, complications of these surgeries have been a major issue, including electrolytes disturbance, stone formation, recurrent pyelonephritis, malignancy, continent stoma malfunctioning and so on.\[[@ref6][@ref7][@ref8]\]

Our preliminary results of managing those patients in a minimally invasive way are promising. We combined an intravesical botulinum-A toxin (BTX-A) injection and Defflux^®^ sub-ureteral injection to manage lower urinary tract dysfunction and vesicoureteral reflux (VUR), as well as trans anal irrigation to manage SI as a total endoscopic and anal irrigation (TEAM^®^) approach.\[[@ref9]\] Here, we present the long-term outcome of this approach with the goal of determining if such a minimally invasive approach can stand the test of time.

MATERIAL AND METHODS {#sec1-2}
====================

Fourteen mayelomeningocele patients with noncompliant neuropathic bladder and bowel, VUR, and urine/SI were prospectively enrolled in our trial of the TEAM^®^ approach. The median age of the patients 6.5 years; all individuals failed to respond to conservative management including anticholinergic, CIC, diet modification and bulking agent and were still incontinent of urine and stool. Thirteen patients furthermore had a high intravesical pressure (detrusor leak point pressure \> 40 cm H~2~O).

The parents/guardians of all patients signed an informed consent for the treatment and follow-up.

Patients underwent cystoscopic intradetrusor injection of BTX-A, 12 U/kg, with a maximum dose of 300 IU.

Of the 22 refluxing ureters, 6 patients exhibited unilateral and 8 patients showed bilateral. Nine patients showed high-grade VUR (bilateral grade 3 or more, or the presence of grades 4 or 5), and 5 patients with low-grade underwent an endoscopic correction using Deflux^®^ at the same time.

Four patients maintained regular usage of fleet enemas and 10 patients started on a Trans anal irrigation system, Peristeen^®^ (Coloplast, Denmark).

After close follow-up in the 1^st^ year, 1^st^ month with history, physical examination and Ultrasound, 2^nd^ month with voiding cystourithro gram (VCUG) and 6^th^ month with urodynamic study, there after patients were followed-up routinely every 6 months with a history, physical examination and ultrasound. On finding of continue to have urinary incontinence (UI) or worsening of hydronephrosis in the ultrasound, we conducted an urodynamic study; otherwise, it\'s conducted yearly. Depending on the result of the urodynamic and the history of UI, the BTX-A injections were repeated.

All patients underwent repeated BTX-A injections with an average interval of 1-year and 6 patients underwent repeated Deflux^®^ injection upon VCUG finding.

Response criteria included a stable, compliant bladder with acceptable capacity given the patient age, VUR resolution, dryness between catheterization, and stool continence.

All patients completed at least 3 years of follow-up; the median duration was 4.3 years.

RESULTS {#sec1-3}
=======

After a median 4.3 years of follow-up, mean maximum bladder capacity increased from 78 ± 35 ml to 200 ± 76 ml (*P* \< 0.0001) and the maximum detrusor pressure decreased from 59 ± 11 cm H~2~O to 29 ± 7 cm H~2~O (*P* \< 0.001).

Twenty-one refluxing ureters (95%) showed complete resolution; 55% after one attempt of Deflux^®^ injection, 40% after 2 attempts and one ureter persisted.

Ten patients (72%) achieved complete dryness between catheterization and 4 still remained incontinent.

Thirteen patients achieved complete stool continence. One patient did not respond and underwent a MACE procedure.

No side-effects were noted in our approach, except for mild abdominal cramps with initial use of Peristeen^®^ in 5 patients out of 10; these cramps disappear spontaneously after a short period of use.

At long-term follow-up, 4 patients (28%) did not exhibit the same initial response and they underwent augmentation cystoplasty due to progressive hydronephrosis and/or persistent UI in 3 patients; these individuals had not responded to repeated Botox injections and they still had high detrusor pressure and low bladder capacity (patients 6, 8, and 13 in [Table 1](#T1){ref-type="table"}). The fourth patient (patient 10, [Table 1](#T1){ref-type="table"}) had a wide bladder neck so bladder neck reconstruction was performed in addition.
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DISCUSSION {#sec1-4}
==========

Early in this century, Schurch *et al*. reported a first attempt of using BTX-A in adults for neuropathic bladder.\[[@ref10]\] In 2002, Schulte-Baukloh *et al*. extended the use of BTX-A in children with encouraging results.\[[@ref11]\] Since that time, many studies have been published proving the efficacy and safety of BTX-A.\[[@ref12][@ref13]\]

Spontaneous resolution of VUR was reported in 43--58% of cases with standard conservative treatment.\[[@ref14]\]

Long-term data showed a low success rate of endoscopic correction of VUR in this group of patients,\[[@ref15]\] particularly if not combined with treating the underlying-bladder-cause.

In our institute, we used to treat patients who failed to respond to conservative measures with combined endoscopic management using intravesical BTX-A and Deflux^®^ sub ureteral injections. This total endoscopic management approach preceded major reconstructive surgery\[[@ref16]\] and we have seen encouraging results with this technique.

Trans anal irrigation to manage SI was used and tested previously in our institute and others\[[@ref17][@ref18][@ref19]\] with good results, in an effort to avoid major surgical reconstruction.

As a result, we extended our approach to the TEAM^®^ approach using a Peristeen^®^ anal irrigation system once with BTX-A and endoscopic treatment for VUR.

Basically the Peristeen^®^ system consists of 3 components: A water bag, pump and rectal tube. The operation of the pump was explained to the family. To enhance their understanding, a video tape was also showed.

We start irrigation with 500 ml of tap water-adjusted accordingly to the patient\'s response-; 3 times a week. After the patient becomes complete dry, the frequency is reduced to twice a week. In case of abdominal cramps (s), our recommendation is to ensure the water temperature is neutralized and/or decrease the amount of irrigation.

Since we have found that the TEAM^®^ approach provides a complete minimally invasive and effective management technique to meet the treatment goals, we recommend considering it as a second-line management for noncompliant bladders or bowels when conservative approaches fail.

Each BTX-A procedure costs approximately \$1000--1500 (around \$2000--3000 per year). Peristeen^®^ consists of a disposable rectal catheter, which cost approximately \$1000/year and Deflux would cost another \$1000. Accordingly, the TEAM^®^ approach would cost an average of \$4000 in the 1^st^ year and around \$3000 yearly thereafter. These costs differ among different countries.

A main limitation is the need for frequent hospitalization for Botox injections, every 6--12 months, and frequent urodynamic studies, which invasive diagnostic tool.

All patients younger than 10 years of age need assistance to use the Peristeen^®^ system.

Moving families not located in the same city would be a challenge to continuing the protocol.

The small number of patients included in this study is one of its weak points. However, our work represents a good start to avoid or delay major reconstructive surgeries. Additional large, multicenter, prospective studies are warranted.

CONCLUSIONS {#sec1-5}
===========

Over long-term follow-up, major reconstruction surgery can be avoidable or delayable. The TEAM^®^ approach is a minimally invasive, safe, simple, and effective way to achieve upper urinary tract protection and improve a person\'s social life by providing urinary and stool continence.
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